Compugen Stock Investor Sentiment

CGEN Stock  USD 1.59  0.02  1.24%   
About 61% of Compugen's investor base is looking to short. The analysis of overall sentiment of trading Compugen stock suggests that many investors are alarmed at this time. Compugen's investing sentiment overview a quick insight into current market opportunities from investing in Compugen. Many technical investors use Compugen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Compugen Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Compugen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
United Therapeutics Completes Enrolment in IPF Study
Yahoo News
over three months ago at zacks.com         
United Therapeutics Completes Enrolment in IPF Study
zacks News
over three months ago at finance.yahoo.com         
uniQure Soars on New Huntingtons Disease Study Data
Yahoo News
over three months ago at finance.yahoo.com         
IDEAYA Up on Upbeat Phase II Bladder Lung Cancer Data
Yahoo News
over three months ago at finance.yahoo.com         
Dianthus Gains 18 percent in the Past Month Heres Why
Yahoo News
over three months ago at zacks.com         
Roche Receives FDA Nod for Vabysmo Prefilled Syringe
zacks News
over three months ago at zacks.com         
Apellis Syfovre Boost Sales, Regulatory Setbacks a Woe
zacks News
over three months ago at finance.yahoo.com         
Annovis Up as Its Lead Candidate Meets Goals in PD Study
Yahoo News
over three months ago at kalkinemedia.com         
Bridging Gaps Building Futures Compugen Partners with Sun Youth for Inclusive Education
news
over three months ago at finance.yahoo.com         
Bridging Gaps Building Futures Compugen Partners with Sun Youth for Inclusive Education
Yahoo News
over three months ago at prnewswire.com         
Bridging Gaps Building Futures Compugen Partners with Sun Youth for Inclusive Education
prnewswire News
over three months ago at finance.yahoo.com         
Bridging Gaps Building Futures Compugen Partners with Sun Youth for Inclusive Education
Yahoo News
over three months ago at finance.yahoo.com         
Bridging Gaps Building Futures Compugen Partners with Sun Youth for Inclusive Education
Yahoo News
over three months ago at zacks.com         
Longboard Up 14 percent as Epilepsy Drug Gets Breakthrough Tag
zacks News
over three months ago at finance.yahoo.com         
The past three years for Compugen investors has not been profitable
Yahoo News
Far too much social signal, news, headlines, and media speculation about Compugen that are available to investors today. That information is available publicly through Compugen media outlets and privately through word of mouth or via Compugen internal channels. However, regardless of the origin, that massive amount of Compugen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Compugen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Compugen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Compugen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Compugen alpha.

Compugen Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Compugen Upgraded to Strong Buy What Does It Mean for the Stock
09/11/2024
2
Compugen to Present New Clinical Data at SITC 2024 - StockTitan
10/07/2024
3
Compugen Strengthens Defence Security Industry with Strategic Acquisition of SynerSolutions
11/04/2024
4
Compugen shareholder returns have been stellar, earning 204 percent in 1 year
11/08/2024
5
Compugen earnings beat by 0.11, revenue topped estimates
11/12/2024
6
Compugen Ltd. Q3 2024 Earnings Call Transcript
11/13/2024
7
Compugen Releases Earnings Results
11/14/2024
8
Compugen Stock Dips Amidst Biotech Sector Movements
11/22/2024
When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:
Check out Compugen Hype Analysis, Compugen Correlation and Compugen Performance.
To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.03
Revenue Per Share
0.48
Quarterly Revenue Growth
3.461
Return On Assets
(0.03)
Return On Equity
(0.16)
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.